Aquinox Pharmaceuticals, a clinical-stage biotech developing novel drug candidates to treat inflammation and cancer, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering. The Vancouver, Canada-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol AQXP. Aquinox Pharmaceuticals initially filed confidentially on November 18, 2013. Jefferies and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
